Resverlogix Announces Participation at the Upcoming Global Chinese Financial Forum (“GCFF”) Virtual Conference 2020 – Investing in Innovation

Resverlogix Announces Participation at the Upcoming Global Chinese Financial Forum (“GCFF”) Virtual Conference 2020 – Investing in Innovation

CALGARY, Alberta, Sept. 08, 2020 (GLOBE NEWSWIRE) — Resverlogix Corp. (“Resverlogix” or the “Company”) (TSX:RVX) announces its participation at the GCFF Virtual Conference 2020 – Investing in Innovation (“GCFF Virtual Conference”) on September 10, 2020. Donald McCaffrey, the Company’s President and CEO, will provide a live video presentation commencing at 10:35 am PST / 1:35 pm EST.
About the GCFF Virtual Conference 2020 – Investing in InnovationRegistration for the GCFF Virtual Conference is complimentary and recommended to be made in advance by using the link HERE. Registration will close one day before the event.The GCFF Virtual Conference, held on September 10, 2020, will connect Chinese investors living throughout North America to the latest investment opportunities in the fast growing innovative sectors of healthcare, life science, technology, clean technology, fintech and cannabis.  Hosted by NAI Interactive Ltd., the bilingual online event will feature public and private company investment opportunities and will be broadcast in English and Mandarin Chinese.An archived link to the presentation will be made available approximately one week after the live event on the Company website HERE.About ResverlogixResverlogix is developing apabetalone (RVX-208), a first-in-class, small molecule that is a selective BET (bromodomain and extra-terminal) inhibitor. Apabetalone is the first therapy of its kind to have been granted US FDA Breakthrough Therapy Designation – for a major cardiovascular indication – to help facilitate a time-efficient drug development program including planned clinical trials and plans for expediting the manufacturing development strategy.BET inhibition is an epigenetic mechanism that can regulate disease-causing genes. Apabetalone is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. This selective inhibition of apabetalone on BD2 produces a specific set of biological effects with potentially important benefits for patients with high-risk cardiovascular disease, diabetes mellitus, chronic kidney disease, end-stage renal disease treated with hemodialysis, neurodegenerative disease, Fabry disease, peripheral artery disease and other orphan diseases, while maintaining a well described safety profile.Resverlogix common shares trade on the Toronto Stock Exchange (TSX:RVX).Follow us on:Twitter: @Resverlogix_RVXLinkedIn: https://www.linkedin.com/company/resverlogix-corp-/For further information please contact:Investor Relations
Email: ir@resverlogix.com
Phone: 403-254-9252
Or visit our website: www.resverlogix.com
This news release may contain certain forward-looking information as defined under applicable Canadian securities legislation, that are not based on historical fact, including without limitation statements containing the words “believes”, “anticipates”, “plans”, “intends”, “will”, “should”, “expects”, “continue”, “estimate”, “forecasts” and other similar expressions. In particular, this news release includes forward looking information related to the potential role of apabetalone in the treatment of patients with high-risk cardiovascular disease, diabetes mellitus, chronic kidney disease, end-stage renal disease treated with hemodialysis, neurodegenerative disease, Fabry disease, peripheral artery disease and other orphan diseases. Our actual results, events or developments could be materially different from those expressed or implied by these forward-looking statements. We can give no assurance that any of the events or expectations will occur or be realized. By their nature, forward-looking statements are subject to numerous assumptions and risk factors including those discussed in our Annual Information Form and most recent MD&A which are incorporated herein by reference and are available through SEDAR at www.sedar.com. The forward-looking statements contained in this news release are expressly qualified by this cautionary statement and are made as of the date hereof. The Company disclaims any intention and has no obligation or responsibility, except as required by law, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

CBJ Newsmakers

Recommended
Marathon Gold Reports Additional Exploration Drill Results from the Valentine Gold ProjectPhase 4 Metallurgical Testing Confirms Recovery Assumptions and Identifies Areas for Optimization and Improvement